1842. Analysis of Telavancin in vitro Activity Tested Against a USA Collection of Staphylococcus aureus Clinical Isolates Causing Hospital-acquired Pneumonia (2013-2014)
Session: Poster Abstract Session: Treatment of HAIs/Antimicrobial Resistant Infections
Saturday, October 10, 2015
Room: Poster Hall
Posters
  • ID WEEK 2015 TLV Poster_layout_v2.pdf (82.1 kB)
  • Background: Telavancin (TLV) is approved in the USA and Europe (methicillin-resistant [MRSA] only) for the treatment of hospital-acquired (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by S. aureus when alternative treatments are not suitable. This study provides a current in vitro activity analysis for TLV and comparators against S. aureus causing HABP in USA hospitals during 2013 2014.

    Methods: 1,353 S. aureus collected from 29 USA sites located in the nine USA Census regions were included. Susceptibility testing was performed based on CLSI guidelines (M07-A10 and M100-S25). MIC interpretation was guided by FDA (2014), CLSI (2015) and/or EUCAST (2015) criteria. MRSA resistant to ≥3 drug classes were defined as MDR.

    Results: TLV had MIC50, MIC90 and MIC100 of 0.03, 0.06 and 0.06 mg/mL, respectively, against methicillin-susceptible, MRSA, non-MDR and MDR subsets. All isolates were inhibited by TLV at the susceptible breakpoint (i.e. ≤0.12 mg/mL). TLV MIC values were at least 16-fold lower than vancomycin (VAN; MIC50/90, 1/1 mg/mL) and linezolid (LZD; MIC50/90, 1/1 mg/mL) MICs against MRSA isolates (all 100.0% susceptible to VAN and LZD). TLV, VAN (MIC50/90, 1/1 mg/mL) and LZD (MIC50/90, 1/1 mg/mL) showed activity against the MDR subset, while other agents had limited coverage. S. aureus with VAN MIC=2 mg/mL had TLV MIC50 (0.06 mg/mL) 2-fold higher than those with VAN MIC at ≤1 mg/mL. However, TLV had MIC100 results of 0.06 mg/mL, regardless of subset.

    Conclusion: TLV had potent in vitro activity against S. aureus causing HABP, including less susceptible and MDR subsets, inhibiting all S. aureus at ≤0.06 mg/mL. These results confirm the potent in vitro activity of TLV against S. aureus causing HABP in USA hospitals.

    Rodrigo E. Mendes, PhD1, Helio S. Sader, MD, PhD1, Robert K. Flamm, PhD1, Jennifer I. Smart, PhD2, David J. Farrell, PhD1 and Ronald N. Jones, MD1, (1)JMI Laboratories, Inc., North Liberty, IA, (2)Theravance Biopharma, South San Francisco, CA

    Disclosures:

    R. E. Mendes, Theravance Biopharma: Research Contractor , Research support

    H. S. Sader, Theravance Biopharma: Research Contractor , Research support

    R. K. Flamm, Theravance Biopharma: Research Contractor , Research support

    J. I. Smart, Theravance Biopharma: Employee , Salary

    D. J. Farrell, Theravance Biopharma: Research Contractor , Research support

    R. N. Jones, Theravance Biopharma: Research Contractor , Research support

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.